Evie Carchman, MD, FACS

Assistant Professor

  • Division of Colorectal Surgery

carchman@surgery.wisc.edu
(608) 263-4224

  • Administrative Assistant: (608) 263-2521

Clinical Science Center
600 Highland Avenue
Madison, WI 53792-7375

Education

  • MD, Medical College of Virginia at Virginia Commonwealth University, Richmond, VA, 2006
  • General Surgery Residency, University of Pittsburgh Medical Center, Pittsburgh, PA, 2013
  • Colon and Rectal Surgery Fellowship, Cleveland Clinic, Cleveland, OH, 2014

Clinical Specialties

Dr. Evie Carchman is a fellowship-trained colon and rectal surgeon. She has special expertise in the treatment of colon cancer, rectal cancer, inflammatory bowel disease, benign conditions of colon, rectum, and anus, and endoscopic treatment of colonic disease. Dr. Carchman utilizes minimally invasive techniques including laparoscopic and single incision laparoscopic surgery for the treatment of colon and rectal disease.

Research Interests

Dr. Carchman’s Research Lab >>

Dr. Carchman’s research interests focus on the pathogenesis and treatment of anal cancer. She has special expertise in the treatment of colon cancer, rectal cancer, inflammatory bowel disease, benign conditions of colon, rectum, and anus, and endoscopic treatment of colonic disease. Dr. Carchman utilizes minimally invasive techniques including laparoscopic and single incision laparoscopic surgery for the treatment of colon and rectal disease.

Recent Publications

  • Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors.
    Gunder LC, Moyer TH, Johnson HR, Auyeung AS, Leverson GE, Zhang W, Matkowskyj KA, Carchman EH
    J Surg Res 2023 Feb; 282: 137-146
    [PubMed ID: 36274448]

  • The use of a topical protease inhibitor, Saquinavir, to alleviate mouse papillomavirus-mediated anal disease.
    Gunder LC, Johnson HR, Green HA, Bilger A, Moyer TH, Zhang W, Ziolkowski MR, Bertrang PA, Carchman EH
    Virology 2022 Nov; 576: 96-104
    [PubMed ID: 36206607]

  • Efficacy of Topically Administered Dihydroartemisinin in Treating Papillomavirus-Induced Anogenital Dysplasia in Preclinical Mouse Models.
    Gunder LC, Blaine-Sauer S, Johnson HR, Shin MK, Auyeung AS, Zhang W, Leverson GE, Ward-Shaw ET, King RE, McGregor SM, Matkowskyj KA, Lambert PF, Carchman EH
    Viruses 2022 Jul 26; 14(8)
    [PubMed ID: 35893697]

  • Do immune inflammatory markers correlate with anal dysplasia and anal cancer risk in patients living with HIV?
    Stem J, Yang Q, Carchman E, Striker R, Sanger CB
    Int J Colorectal Dis 2022 May; 37(5): 983-988
    [PubMed ID: 35332364]

  • PI3K/mTOR inhibition prevents anal cancer in mice with established low-grade anal dysplasia.
    Gunder LC, Moyer TH, Rademacher BL, Auyueng AS, Leverson G, Zhang W, Matkowskyj KA, Carchman EH
    Exp Mol Pathol 2022 Apr; 125: 104752
    [PubMed ID: 35183509]

All Publications on PubMed